Compare Align Technology, Inc. (ALGN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs Mesoblast Limited — how do they compare? Align Technology, Inc. trades at $171.33 (market cap $12.29B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: Align Technology, Inc. is far larger — about 5.6× Mesoblast Limited's market cap, and Align Technology, Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| ALGN | MESO | |
|---|---|---|
Market Cap | $12.29B | $2.21B |
Sector | Health | Technology |
52-Week High | $197.51 | $20.96 |
52-Week Low | $124.88 | $12.88 |
Enterprise Value | $11.30B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $176.04, up 1.37% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported record Q2 2026 revenue of $1.06 billion, driven by strong clear aligner volume growth. Analyst sentiment is positive, with 73% recommending buy, and institutional activity shows mixed positioning amid strategic initiatives like board changes and patent wins in China.
The outlook remains favorable due to solid fundamentals and international expansion, but risks include competitive pressures in digital dentistry and reliance on North American market stability. Earnings growth and margin improvements are key catalysts, though valuation multiples near five-year lows suggest potential upside if execution continues.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
